ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
29 Oct 2023 10:10

A-H Premium Weekly (Oct 27th): Beigene, CMS, Guangzhou Auto, China Longyuan

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Beigene, China Merchants Securities, Guangzhou Auto, China...

Logo
402 Views
Share
23 Oct 2023 17:39

Quiddity HK Connect SOUTHBOUND Flows (To 20 Oct 23): Meituan, SMIC, Great Wall!

SOUTHBOUND flows last week were still mildly positive making it 13 weeks in a row. Great Wall Motors is finally a large net buy.

Logo
447 Views
Share
17 Oct 2023 09:18

Innovent Biologics Placement (1801.HK) - There Is No Such Thing as a Free Lunch

Innovent's recent strong share price performance reflects the market's enthusiasm for weight loss drugs. Compared with weight loss pipeline of...

Logo
804 Views
Share
bullishJapan Post Bank
15 Oct 2023 05:50

Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, TOPIX FFW, SSE50, AS51, ChiNext, Kenedix, Liontown

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
743 Views
Share
10 Oct 2023 06:11

HSCEI Index Rebalance Preview: One Change; Capping Impact Increases

China Unicom IN, Zhongsheng Group OUT likely. Passive trackers will need to trade over 2x ADV on both stocks. Meituan, Alibaba, Tencent capped...

Logo
697 Views
Share
x